See the DrugPatentWatch profile for polivy

The drug directly compared to Polivy in trials is rituximab [1]. Rituximab is a monoclonal antibody used to treat certain types of cancer, including non-Hodgkin's lymphoma [2].

Polivy, also known as polatuzumab vedotin-piiq, is a type of antibody-drug conjugate used to treat relapsed or refractory diffuse large B-cell lymphoma [3]. In clinical trials, Polivy was directly compared to rituximab in combination with bendamustine, another chemotherapy drug [1].

According to DrugPatentWatch.com, Polivy was approved by the FDA in June 2019 and is manufactured by Genentech, a subsidiary of Roche [4]. Rituxan, the brand name for rituximab, has been on the market since 1997 and is also manufactured by Genentech [5].

Sources:
[1] <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polivy-polatuzumab-vedotin-piiq-treat-diffuse-large-b-cell-lymphoma>
[2] <https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/chemotherapy/rituxan.html>
[3] <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/important-safety-information-polivy-polatuzumab-vedotin-piiq-injection>
[4] <https://www.drugpatentwatch.com/drugs/polivy>
[5] <https://www.drugpatentwatch.com/drugs/rituxan>